Chemistry & pharmacokinetics
Amycretin is a large peptide, roughly 68 amino acids, because it fuses two agonist regions into one chain.
A 68-amino-acid fusion, engineered to last
Amycretin is a large peptide, roughly 68 amino acids, because it fuses two agonist regions into one chain. A fatty-acid tail lets it cling to blood albumin, and stabilizing tweaks keep it from being destroyed by enzymes, so it can be dosed weekly by injection or daily as a pill.
This unit opens up that molecular design and follows the drug through the body: how it is built, why it lasts, and why both formulations climb the dose slowly.
Key terms
The molecule, module by module
Amycretin is a 68-amino-acid peptide (about 7847 daltons) with several functional modules: a GLP-1-active region, an amylin-active region, a short linker joining them, a fatty-acid tail for albumin binding, and stabilizing tweaks. Tap each module to see its job.
The albumin-binding acyl chain and the enzyme-resistant substitution are the same two tricks used in semaglutide; the novelty here is the fused amylin part, not the half-life chemistry. Fusing two agonist regions is why amycretin is roughly twice the length of either parent hormone. The modular picture makes the engineering legible: two arms, one linker, a tail to last, and tweaks to survive.
AdvancedWhy albumin binding extends the half-life
Small peptides are cleared fast by the kidney and chewed up by enzymes. The general principle is that by clinging to albumin, the most abundant blood protein, a small peptide becomes part of a large complex that the kidney filters less readily. What the sponsor reports for amycretin is narrower than that story: the acyl chain at position K37 enables reversible albumin binding and provides a long systemic half-life. The depot picture is the standard explanation of why a peptide can be dosed weekly, not a measurement made on this molecule.